Abstract:Abstract Background: Breath analysis is a promising noninvasive screening technique that offers a wide range of probable possibilities to facilitate early diagnosis of lung cancer (LC). Method: Exhaled breath samples of 352 subjects were analyzed to detect C6∼C30 VOCs through thermal desorption coupled with gas chromatography-mass spectrometry (TD-GC-MS). Data were divided into three categories Lung Cancer (LC), Benign Pulmonary Disease (BPD) and Healthy control (HC). Statistical classification models were used to analyze VOCs to distinguish between HC, BPD and LC patient's early and advanced stages. Receiver operator characteristics (ROC) curves were used to select different VOCs to evaluate the accuracy, specificity, and sensitivity of the diagnostic model. Results: The analysis resulted that 10,9,11 and 10 VOCs have a significant correlation to discriminate Histology, stage, BPD from LC and HC from LC. The diagnostic model predicted accuracy, sensitivity, and specificity of NSCLC vs. SCLC is 92%, 96% and 90% with area under curve AUC>0.913. As of ROC curve with AUC>0.819 has distinguished Stage I-II vs. stage III-IV with accuracy, sensitivity, and specificity 72%, 84%, and 80%. Whereas the ROC curve with AUC>0.795 has distinguished BPD from LC with accuracy, sensitivity, and specificity 83%, 89%, and 84%. While ROC curve with AUC>0.945, accuracy, sensitivity and specificity 92%, 96%, and 90% have distinguished HC from LC. Conclusion: This study confirms that TD GC-MS is a sensitive and dependable method to distinguish the VOCs in exhaled breath. We have witnessed significant differences in breath of BPD, HC and LC subjects. Where 10,8,11 and 10 VOCs have distinguished between early from the advance stage, NSCLC from SCLC, BPD from LC and HC from LC. These VOCs has the potential to help improve LC diagnosis and prognosis. However, with the expansion of multi centers to other regions could result in more vital findings and will help improve breath analysis and the diagnosis standard. Keywords: Breath Analysis, VOC markers, lung cancer, TD-GC-MS. Citation Format: Kanhar Ghulam Muhammad, Channa Madeeha, Fu Wei, Xu Lin Xin, Yanjie Hu, Kejing Ying, Jun Liu, Xing Chen. Volatile organic compounds (VOCs) from exhaled Breath for lung cancer Staging using TD-GC-MS [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 744.

Breath Analysis via Gas Chromatography-Mass Spectrometry (GC-MS) in Chronic Coronary Syndrome (CCS): A Proof-of-Concept Study

Abstract 744: Volatile Organic Compounds (vocs) from Exhaled Breath for Lung Cancer Staging Using TD-GC-MS

The research on early detection of lung cancer with exhaled volatile organic compounds

A Study of the Volatile Organic Compounds Exhaled by Lung Cancer Cells in Vitro for Breath Diagnosis

Optimization of Volatile Markers of Lung Cancer to Exclude Interferences of Non-Malignant Disease

Volatile organic compounds (VOCs) in exhaled breath as a marker of hypoxia in multiple chemical sensitivity

Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease

Colorectal Cancer Diagnosis through Breath Test Using a Portable Breath Analyzer—Preliminary Data

Rapid Point-of-Care Exhaled Breath Analysis for Lung Cancer Diagnosis Using a Micro Gas Chromatography System: A Pilot Study

Exhaled Breath Analysis for the Diagnosis and Assessment of Endoluminal Gastrointestinal Diseases

A dual center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD

Breathomics: may it become an affordable, new tool for early diagnosis of non-small-cell lung cancer? An exploratory study on a cohort of 60 patients

Target Analysis of Volatile Organic Compounds in Exhaled Breath for Lung Cancer Discrimination from Other Pulmonary Diseases and Healthy Persons

Exhaled volatile organic compounds for diagnosis and monitoring of asthma

Breathome discriminate Ischemic Heart Disease

Comparison of Targeted and Untargeted Approaches in Breath Analysis for the Discrimination of Lung Cancer from Benign Pulmonary Diseases and Healthy Persons

Metabolomics Diagnosis of COVID-19 from Exhaled Breath Condensate

Breathomics to monitor interstitial lung disease associated with systemic sclerosis

Breath Fingerprint of Colorectal Cancer Patients Based on the Gas Chromatography–Mass Spectrometry Analysis

Application of chemoresistive gas sensors and chemometric analysis to differentiate the fingerprints of global volatile organic compounds from diseases. Preliminary results of COPD, lung cancer and breast cancer

Combination of real-time and hyphenated mass spectrometry for improved characterisation of exhaled breath biomarkers in clinical research